• Three posters provide further evidence of the high levels of accuracy of the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose monitoring systems
• One poster presents a new methodology for revealing the differences between blood glucose monitoring systems
Paris, France, 16 February 2017 - At the 10th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), Ascensia Diabetes Care presented data from four scientific posters. Three of these posters provided further evidence for the high levels of accuracy of the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose monitoring systems (BGMSs), including evidence to show that the CONTOUR®NEXT ONE meets the tightened accuracy requirements of the FDA Over-the-Counter BGMS Guidance recently issued in 2016. The fourth poster presented a new methodology for revealing the differences between multiple BGMSs that meet EN ISO 15197:2015 (ISO 15197:2013) accuracy criteria. The ATTD 2017 began yesterday in Paris, France and continues through February 18, 2017.
In two posters (ATTD7-0166 and ATTD7-0177) the accuracy of the Second-Chance® sampling feature of the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose monitoring systems was evaluated. This feature prompts users to reapply blood if there is not enough the first time, helping to avoid lancing for a second time and the wasting of strips. A laboratory and clinical study were conducted for each system to examine accuracy in each setting. The clinical studies used intentionally insufficient blood samples to produce Second-Chance® sampling opportunities. This was followed by a reapplication, and the results from the systems were compared with YSI reference results.
In the clinical study of 52 subjects using the CONTOUR®NEXT ONE BGMS, 100% of subject fingertip self-test results fell within ±15 mg/dL or ±15% of YSI reference results and 92.9% of self-test results were within ±10 mg/dL or ±10% of YSI reference results. In the clinical study of the CONTOUR®PLUS ONE BGMS, also including 52 subjects, 95% of results fell within ±15 mg/dL or ±15% of YSI reference results and 90.7% of self-test results were within ±10 mg/dL or ±10% of YSI reference results.1,2
Dr. Lars Krinelke, Medical Director, Global Medical Affairs at Ascensia Diabetes Care, said: “For Second-Chance® sampling to benefit people with diabetes and their healthcare professionals, it is of great importance that this feature delivers the benefit of accuracy that is similar to the levels of accuracy observed with the first attempt at blood glucose testing. These studies confirm the high levels of accuracy of the Second-Chance® sampling feature in the CONTOUR®NEXT ONE and the CONTOUR®PLUS ONE blood glucose monitoring systems. Second-Chance® sampling has the potential to help people with diabetes reduce the costs of test strips by offering a second opportunity to obtain highly accurate readings with the original strip that was used.”
The third poster (ATTD7-0280) assessed the accuracy of the CONTOUR®NEXT ONE BGMS used by subjects with and without diabetes, when evaluated against the criteria of the FDA OTC BGMS Guidance 2016. This guidance requires that 95% of results are within ±15% and 99% are within ±20% of a comparator reference method across the entire tested range. In this study, the results for subject fingertip self-tests showed that 99.5% were within ±15% and 99.7% were within ±20%, demonstrating that the CONTOUR®NEXT ONE system meets these criteria.3
The final poster (ATTD7-0272) presented a new method for distinguishing differences between BGMSs that meet the ISO accuracy criteria. This new methodology uses probability curves to examine accuracy across the entire blood glucose range, and showed that there can be differences between systems that have met the ISO accuracy criteria.4 This type of information might be important and especially useful in the low blood glucose range where small errors in BGMS measurements can have substantial consequences for patient-related outcomes, particularly related to hypoglycemia risk.
Michael Kloss, CEO of Ascensia Diabetes Care, added: “These findings support Ascensia Diabetes Care’s ongoing commitment to scientific research. The accuracy data demonstrate our ongoing commitment to ensuring excellence in our products and the new methodology presented shows our contribution to bold innovations and scientific discovery.”
The CONTOUR® NEXT ONE and CONTOUR® PLUS ONE BGMSs received CE Mark approval in Europe in April 2016, and the CONTOUR®NEXT ONE BGMS received U.S. Food and Drug Administration (FDA) clearance in November 2016.
